Harpreet S. Dhaliwal, Chief Technical Ops Officer of Vaxcyte, Inc. (NASDAQ:PCVX), filed a Form 4 on November 13, 2026, disclosing the exercise of stock options and the sale of common stock on November 11, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Dhaliwal exercised a fully vested stock option covering 17,000 shares of common stock at an exercise price of $24.79 per share on November 11, 2026.
  • Shares sold - tranche 1: 7,135 shares were sold at a weighted-average price of $67.33, with individual prices ranging from $66.76 to $67.755.
  • Shares sold - tranche 2: 9,345 shares were sold at a weighted-average price of $68.156, with individual prices ranging from $67.76 to $68.75.
  • Shares sold - tranche 3: 520 shares were sold at a weighted-average price of $68.819, with individual prices ranging from $68.76 to $68.85.
  • Remaining beneficial ownership: Following all reported transactions, Dhaliwal directly beneficially owned 68,085 shares of common stock and 11,000 stock options.
  • Trading plan: All sales were effected pursuant to a Rule 10b5-1 trading plan adopted on April 6, 2026.

Vaxcyte Chief Technical Ops Officer Reports Option Exercise and Three-Tranche Stock Sale

According to the Form 4 filed with the SEC on November 13, 2026, Harpreet S. Dhaliwal, identified as Chief Technical Ops Officer of Vaxcyte, Inc., reported transactions in the company's common stock occurring on November 11, 2026. The filing indicates that a stock option with an exercise price of $24.79 per share and an expiration date of March 2, 2032 was exercised for 17,000 shares under transaction code "M." The option was described in the filing as "fully vested and exercisable." Following the exercise, Dhaliwal's direct beneficial ownership of common stock increased to 85,085 shares before the subsequent sales.

The filing reports three separate sale transactions, all conducted under transaction code "S" and all attributed to a Rule 10b5-1 trading plan adopted on April 6, 2026. The first tranche involved 7,135 shares sold at a weighted-average price of $67.33, the second involved 9,345 shares at a weighted-average price of $68.156, and the third involved 520 shares at a weighted-average price of $68.819. The filing notes that full price-by-price information for each tranche is available upon request to the SEC, the issuer, or a security holder of the issuer.

The filing also includes a note stating: "No other shares of common stock subject to the restrictions on transfer set forth in a Lock-Up Agreement dated October 6, 2026 were sold by the Reporting Person." After all transactions, Dhaliwal's direct beneficial ownership stood at 68,085 shares of common stock and 11,000 remaining stock options. The Form 4 was signed by Peter N. Efremenko as Attorney-in-Fact on behalf of Dhaliwal.

What Was Disclosed

The filing disclosed the exercise of 17,000 vested stock options at $24.79 and the subsequent sale of 17,000 shares of Vaxcyte common stock across three price tranches on November 11, 2026, all under a pre-established Rule 10b5-1 plan, leaving Dhaliwal with 68,085 shares and 11,000 options.